Sam Reynolds retweetledi

we don't have nearly enough prediction markets on clinical trials and it's a goldmine sitting in plain sight
martin shkreli claims he made over $100M shorting pharma
his edge wasn't insider info, it was reading publicly available clinical trial data that nobody else bothered to look at
every FDA filing, every interim result, every adverse event report, every endpoint analysis were all public
a pharmacist who reads the molecular data has more edge on these outcomes than any wall street analyst running a DCF model. this is one of the few areas where domain expertise destroys financial expertise and there's almost no prediction market infrastructure built for it
whoever builds deep clinical trial prediction markets unlocks something powerful where the market itself becomes the information product
you're broadcasting what the most informed people in the world actually think about the science
the opportunity is wide open
English

























